ConductScience.org, home

Comparison · NCT06729593-fd33f3f8

Remdesivir + SOC vs Placebo + SOC: Number of Participants Who Died Through Day 90

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Remdesivir + SOC vs Placebo + SOC: Number of Participants Who Died Through Day 90. Trial comparisons, record NCT06729593-fd33f3f8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06729593-fd33f3f8

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3860.2570.534wilson
Risk in group 20.4650.3250.611wilson
Risk difference, group 1 minus group 2-0.0788-0.2730.125newcombe hybrid score
Risk ratio, group 1 over group 20.8310.5081.36log
Odds ratio, group 1 over group 20.7240.3091.7log
Number needed to treat, for one fewer participant with the outcome on Remdesivir + SOC than on Placebo + SOC12.7from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Remdesivir + SOC
Arm includes all participants who received Remdesivir and were randomized under strata 1 and 3 from the master protocol (NCT04843761).~Remdesivir: Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.~Corticosteroid: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
1744OG000
Group 2Placebo + SOC
Arm includes all participants who received Remdesivir Placebo and were randomized under strata 1 and 3 from the master protocol (NCT04843761).~Remdesivir Placebo: Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.~Corticosteroid: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
2043OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Died Through Day 90
Description
Time frame
Through Day 90
Population

Source ClinicalTrials.gov

Trial

Title
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT number
NCT06729593
Phases
PHASE3
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Results first posted
2025-10-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT06729593-fd33f3f8